Inhibition of NKCC1 by specific inhibitors has been shown to mitigate approximately half the volume of the tissue damage following cerebral ischemia and also improve sensory-motor function and reduce mortality[19]. This evidence concerns the gene SLC12A2 and brain ischemia.